Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

BACKGROUND: Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage. Thus, the concomitant use of novel compounds represents a critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Caponigro, Francesco, Di Gennaro, Elena, Ionna, Franco, Longo, Francesco, Aversa, Corrado, Pavone, Ettore, Maglione, Maria Grazia, Di Marzo, Massimiliano, Muto, Paolo, Cavalcanti, Ernesta, Petrillo, Antonella, Sandomenico, Fabio, Maiolino, Piera, D’Aniello, Roberta, Botti, Gerardo, De Cecio, Rossella, Losito, Nunzia Simona, Scala, Stefania, Trotta, Annamaria, Zotti, Andrea Ilaria, Bruzzese, Francesca, Daponte, Antonio, Calogero, Ester, Montano, Massimo, Pontone, Monica, De Feo, Gianfranco, Perri, Francesco, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123351/
https://www.ncbi.nlm.nih.gov/pubmed/27884140
http://dx.doi.org/10.1186/s12885-016-2957-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123351/
https://www.ncbi.nlm.nih.gov/pubmed/27884140
http://dx.doi.org/10.1186/s12885-016-2957-y

Ejemplares similares